Organoids And Spheroids Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Organoids And Spheroids Market Analysis

The Organoids And Spheroids Market size is estimated at USD 0.98 billion in 2024, and is expected to reach USD 1.97 billion by 2029, growing at a CAGR of 14.98% during the forecast period (2024-2029).

Organoids are 3D, lab-grown miniatures that mimic the structure and function of real organs, derived from stem cells or progenitor cells to model tissues like the liver, brain, or kidneys for research on organ development and disease. In contrast, spheroids are simpler 3D cell aggregates that form in suspension and are used to study basic cellular behaviors such as growth and drug responses. The organoids and spheroids market is experiencing dynamic growth fueled by advancements in 3D cell culture technology and a growing focus on personalized medicine.

Innovations in single-particle isolation and dispensing are crucial in this development, significantly impacting research and applications in drug discovery, personalized medicine, and regenerative therapies. For instance, in July 2024, SEED Biosciences introduced Dispen3D, a key advancement in single-particle dispensing technology. This cutting-edge platform utilizes impedance-based dispensing technology and advanced data analysis software to precisely and gently handle 3D cellular models, including spheroids and organoids. By enabling high-precision isolation and dispensing, Dispen3D offers researchers a powerful tool for conducting detailed experiments and accelerating the transition from traditional animal models to sophisticated 3D models. Therefore, such innovative technology enhances research capabilities that drive the growth of the organoids and spheroids market.

Moreover, colorectal cancer (CRC) is a complex and heterogeneous disease, and advancements in three-dimensional (3D) culture models have proven inadequate for accurately studying its molecular characteristics and drug responses. For instance, in a study published in the Journal of Exploration of Targeted Anti-tumor Therapy in April 2024, spheroids derived from dissociated CRC cells or tissues better mimicked the tumor microenvironment (TME). They demonstrated increased chemoresistance compared to 2D models, as seen in co-culture studies with fibroblasts and cancer-associated fibroblasts (CAFs). Also, co-cultured CRC spheroids with fibroblasts showed reduced drug sensitivity to 5-FU and regorafenib, reflecting clinical conditions more closely than 2D models.

Additionally, per the same source mentioned above, organoids, which can be developed from normal and cancerous colonic tissues, retain the genomic and phenotypic heterogeneity of primary tumors, making them a promising tool for drug screening and personalized medicine. Therefore, such studies represent a significant improvement and are expected to grow, driving market expansion.

The organoids and spheroids market is experiencing rapid growth as advanced 3D cell culture models become increasingly vital for drug discovery, disease modeling, and toxicity testing. For instance, in March 2023, MIMETAS launched OrganoReady colon and kidney organoid tubules, which offer assay-ready, donor-relevant 3D models that provide a more accurate representation of human tissues without needing stem cell reprogramming. The collaboration with HUB Organoid Technology and the use of MIMETAS’ proprietary OrganoPlate microfluidic platform enables the creation of perfused tubular organoids, ideal for applications like mechanistic toxicology and drug-induced organ injury testing, aligning with the FDA Modernization Act 2.0. Thus, such rising launches accelerate the adoption of organoids and spheroids in the pharmaceutical and biotech industries, thus driving market growth.

However, the high cost of technology, stringent regulatory scenario, and standardization challenges restrain market growth.

Organoids And Spheroids Market Trends

Personalized Medicine Segment is Expected to Witness Significant Growth Over the Forecast Period

Organoids And Spheroids Market Industry Segmentation

Organoids are 3D mini-organs grown from stem cells that mimic organ structure and function and are used for research on development and disease. Spheroids are simpler 3D cell clusters that study cellular behaviors like growth and drug responses.

The organoids and spheroids market is segmented into type, application, end user, and geography. By type, the market is segmented into organoids (intestinal organoids, hepatic organoids, pancreatic organoids, neural organoids, and other organoids {lung, kidney, and gastric, among others}) and spheroids (multicellular tumor spheroids, neurospheres, hepatospheres, mammospheres, and other spheroids {embryoid bodies, etc.}), application (disease modeling, drug discovery and toxicology screening, regenerative medicine, stem cell research, personalized medicine, and other applications {gene editing and immuno-oncology, among others}), end user (pharmaceutical and biotechnology companies, academic and research institutes, hospitals and diagnostic centers, contract research organizations {CROs}, and other end users {biobanks, stem cell banks}). By geography, the market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East and Africa. The report also offers the market size and forecasts for 17 countries across the region. For each segment, the market sizing and forecasts were made on the basis of value (USD).